Shandong Lukang Pharmaceutical Co.,Ltd.

600789

CNE000000P61

Shandong Lukang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The Company's primary products include pharmaceutical preparation products, semi-synthetic antibiotic raw materials, veterinary antibiotics and antibiotic raw materials and others. The Company is also involved in the production and distribution of pharmaceutical intermediates. The Company distributes its products in domestic and overseas markets.

Employees

6,484

Sector

Pharmaceuticals

Calendar

27/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 09/09/2024			5-day change	1st Jan Change
7.030 ^CNY	+0.14%		-1.95%	-1.54%

08-21	Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
08-14	Lukang Pharmaceutical's Unit Gets Nod to Market Adenosylcobalamin Capsules	MT

Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-21	CI
Lukang Pharmaceutical's Unit Gets Nod to Market Adenosylcobalamin Capsules	08-14	MT
China Approves Lukang Pharma's Anti-Asthma Injection	05-29	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Lukang Pharmaceutical Gets Nod to Produce Parkinson's Disease Drug	01-25	MT
Lukang Pharmaceutical's Piperacillin Sodium, Tazobactam Sodium Injection Passes Regulatory Evaluation	11-13	MT
Lukang Pharmaceutical's Ampicillin Sodium and Sulbactam Sodium Pass Regulatory Evaluation	11-02	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Lukang Pharmaceutical's Ornidazole Tablets Passes Regulatory Evaluation	18/09/23	MT
Shandong Lukang Pharmaceutical Co.,Ltd.(XSSC:600789) added to S&P Global BMI Index	18/09/23	CI
Lukang Pharma Generic Hypertension Drug Passes Regulatory Evaluation	08/09/23	MT
Lukang Pharmaceutical's Cefaclor Granules Passes Chinese Drug Regulator's Evaluation	06/09/23	MT
Lukang Pharmaceutical's Cefixime Tablets Passes Regulator's Evaluation	18/08/23	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
Lukang Pharmaceutical's Cefminox Sodium for Injection Passes Regulatory Evaluation	25/07/23	MT
Lukang Pharmaceutical's Cefaclor Capsules Passes Regulatory Evaluation	12/07/23	MT
Lukang Pharma's Cefazolin Sodium for Injection Passes Drug Regulator's Evaluation	18/05/23	MT
Lukang Pharma's Ampicillin Sodium for Injection Passes Regulatory Evaluation	09/05/23	MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	18/04/23	CI
Lukang Pharma Gets Nod to Market Anti-Arthritis Drug Ingredient	23/02/23	MT
Lukang Pharma’s Benzyl Alcohol Wins Marketing Approval in China	09/02/23	MT
Shandong Lukang Pharmaceutical Raising 1.2 Billion Yuan to Fund Expansion Plans	03/01/23	MT
Lukang Pharma Gets Regulatory Nod for Anti-Pneumonia Drug	20/12/22	MT
Lukang Pharmaceutical Gets Approval for Diabetes Treatment Tablet	16/11/22	MT

Shandong Lukang Pharmaceutical Co.,Ltd.

Equities

600789

CNE000000P61

Pharmaceuticals

Latest news about Shandong Lukang Pharmaceutical Co.,Ltd.

Chart Shandong Lukang Pharmaceutical Co.,Ltd.

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise